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Humanmannose-binding lectin (MBL) encoded by theMBL2 gene is a pattern recognition protein and has been associated with
many infectious diseases, including malaria. We sought to investigate the contribution of functionalMBL2 gene variations to
Plasmodium falciparummalaria in well-defined cases and in matched controls. We resequenced the 8.7 kb of the entireMBL2
gene in 434 individuals clinically classified with malaria from regions of India where malaria is endemic. The study cohort in-
cluded 176 patients with severe malaria, 101 patients with mild malaria, and 157 ethnically matched asymptomatic individuals.
In addition, 830 individuals from 32 socially, linguistically, and geographically diverse endogamous populations of India were
investigated for the distribution of functionalMBL2 variants. TheMBL2221C (X) allelic variant is associated with increased
risk of malaria (mild malaria odds ratio [OR] 1.9, corrected P value [PCorr] 0.0036; severe malaria OR 1.6, PCorr 0.02).
The exon1 variantsMBL2*B (severe malaria OR 2.1, PCorr 0.036; mild versus severe malaria OR 2.5, PCorr 0.039) and
MBL2*C (mild versus severe malaria OR 5.4, PCorr 0.045) increased the odds of having malaria. The exon1MBL2*D/*B/*C
variant increased the risk for severe malaria (OR 3.4, PCorr 0.000045). The frequencies of lowMBL haplotypes were signifi-
cantly higher in severe malaria (14.2%) compared to mild malaria (7.9%) and asymptomatic (3.8%). TheMBL2*LYPA haplo-
types confer protection, whereasMBL2*LXPA increases the malaria risk. Our findings in Indian populations demonstrate that
MBL2 functional variants are strongly associated with malaria and infection severity.
Malaria is one of the major causes of morbidity and mortalityin tropical and subtropical countries, with an estimated 1.24
million mortality in 2010, mostly in Africa (1, 2). Humanmalaria
is caused by the hematoprotozoan parasite of the genus Plasmo-
dium with five different species (i.e., P. falciparum, P. vivax, P.
ovale, P. malariae, and P. knowlesi) infecting humans. The patho-
genesis of malaria is complex and multigenic, and the severity
depends on the complex interplay between host genetic makeup,
the parasite virulence, and its transmission dynamics, as well as
the host immune responses (3, 4). Innate immune components
mediate humoral immune responses to malaria by involving var-
ious complement proteins (5, 6). The innate immune system
mainly relies on diverse pattern-recognizing receptor or soluble
pathogen-recognizing molecules (PRMs) (7, 8) that recognize
molecular motifs on the surfaces of microorganisms. Mannose-
binding lectin (MBL) is a C-type soluble PRMs secreted by the
liver as part of the acute-phase response and plays an important
role in the recognition, initiation, regulation, and amplification of
innate immune defense (9). The human MBL encoded by MBL2
mapped to 10q21.1 is a 32-kDa polypeptide, made up of 248
amino acids, having an N-terminal cysteine-rich segment, a col-
lagen-like domain, a helical coiled-coil neck region, and a C-ter-
minal glucoconjugate recognition domain (10). The structural
subunit is a homotrimer of 96 kDa with a triple helix at its colla-
gen-like domain. The functional MBL complex is a bouquet-like
hexamer that circulates in serum (11, 12). MBL binds to an array
of glycoconjugates on the surface of bacteria, yeasts, viruses, and
parasitic protozoa, including P. falciparum (13), and activates the
complement system. MBL interacts with MBL-associated serine
proteases (MASP-1, -2, and -3 and Map19) and activates the
membrane attack complex or complement-mediated phagocyto-
sis (9, 11, 13) and also regulates the release of proinflammatory
cytokines (14).
MBL2 genetic variants have been shown to associatewithmany
infectious diseases such as malaria, leishmaniasis, leprosy, schis-
tosomiasis, trypanosomiasis, HIV infection, and autoimmune dis-
ease (9, 14–21). Three single-nucleotide polymorphisms (SNPs) in
promoters and a 5= untranslated region [(550:rs11003125:
GC, H/L), (221:rs7096206 GC, Y/X), and (4:rs7095891
CT, P/Q)] are functionally characterized to alter the transcrip-
tional levels and hence the serumMBL levels (22–24). In particu-
lar, promoter alleles550L,221X, and4P are associated with
lower MBL serum levels (13), whereas three nonsynonymous
structural variants in exon1 of MBL2 at codons 52, 54, and 57 of
the collagen-like domain [(rs5030737: p.Arg52Cys:MBL2*D),
(rs1800450: p.Gly54Asp:MBL2*B), and (rs1800451: p.Gly57Glu:
MBL2*C)] independently interfere with the formation of higher
MBP oligomers, leading to alterations in the functional activity of
the protein and their circulating levels (11, 25–30). Such structural
variant alleles have been designated as O haplotype, whereas the
normalMBL2 allele has been designated as A haplotype (31). Fur-
ther, these six SNPs (L/H, X/Y, P/Q, MBL2*D, MBL2*B, and
MBL2*C) have been shown to be in linkage disequilibrium (LD)
and form eight common “secretor haplotypes” (HYPA, LYPA,
Received 21 August 2013 Returned for modification 24 September 2013
Accepted 30 September 2013
Published ahead of print 14 October 2013
Editor: J. H. Adams
Address correspondence to Kumarasamy Thangaraj, thangs@ccmb.res.in.
Supplemental material for this article may be found at http://dx.doi.org/10.1128
/IAI.01041-13.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.
doi:10.1128/IAI.01041-13
52 iai.asm.org Infection and Immunity p. 52–61 January 2014 Volume 82 Number 1
 o
n
 April 20, 2017 by guest
http://iai.asm
.org/
D
ow
nloaded from
 
LYQA, LXPA,HYPD, LYPB, LYQC, and LYPD) (8, 25, 32). These
secretor haplotypes not only regulate the serum levels of func-
tional MBL molecule but also modulate the complement activa-
tion (22, 26, 27, 33, 34). MBL2*HYPA, LYQA, and LYPA are
associated with high expression of MBL protein, whereas
MBL2*LXPA, HYPD, LYPB, and LYQC are associated with low
expression of MBL protein (32, 35) and modulate the MBL con-
centration in healthy individuals from undetectable levels to
1,000-fold (36, 37).
To the best of our knowledge, no studies to date have investi-
gated the association of MBL2 functional variants with malarial
susceptibility in Indian populations.We sought here to investigate
the contribution of polymorphisms in the entireMBL2 gene with
P. falciparum malaria infection in well-defined malaria cases and
in matched controls. Moreover, Indian populations are unique in
their origin and have developed unique variations due to isolation
from rest of the world for thousands of years (38, 39). Since the
entire Indian subcontinent represents an area where malaria is
endemic, we extended our study to 32 socially, linguistically, and
geographically diverse endogamous Indian populations who live
in this region.
MATERIALS AND METHODS
Sampling.A total of 1,264 individuals were included in the present study,
including 434 ethnically matched case-control samples that included
asymptomatic individuals (n 157, mean age of 29.7 19.62 years, and
amale/female ratio of 2:65), individuals withmildmalaria (n 101,mean
age of 30.24 15.71 years, and amale/female ratio of 67:34), and patients
with severe malaria (n  176, mean age of 26.13  12.32 years, and a
male/female ratio of 103:73), as well as 830 individuals from 32 socially,
linguistically, and geographically diverse endogamous populations of In-
dia. Patient samples were collected from those who were visiting or ad-
mitted with malaria for treatment at Ispat General Hospital, Rourkela,
India, and Pt. Jawaharlal NehruMemorialMedical College, Raipur, India.
These are regions of India where P. falciparum is endemic. Microscopic
results for all of the samples were revalidated for the presence of P. falcip-
arum by PCR using species-specific primers; targeting conserved the 18S
rRNA gene of the parasite (40). Samples were clinically characterized ac-
cording to World Health Organization (WHO) 2010 guidelines (41) and
as described previously (42, 43).WHOguidelines define severemalaria by
the presence of one or more of the facultative signs of severe malaria:
cerebral malaria, convulsions, hypoglycemia, hemoglobinuria, prostra-
tion, and respiratory distress (acidotic breathing). Laboratory findings
included hypoglycemia (blood glucose level of 2.2 mmol/liter or 40
mg/dl), metabolic acidosis (plasma bicarbonate level, 15 mmol/liter),
severe normocytic anemia (hemoglobin,50 g/liter; packed cell volume,
15%), hyperparasitemia (2% of infected red blood cells [RBCs] or
100,000 infected cells/l in low-transmission areas or 5% of infected
RBCs or 250,000 infected cells/l in high-transmission areas), hyperlac-
tatemia (lactate, 5 mmol/liter), renal impairment (serum creatinine,
265 mol/liter), and a Blantyre coma score of3. Similarly, mild ma-
laria is defined by a parasitemia of 1,000 to 50,000/l on admission, no
schizontemia, circulating leukocytes containingmalarial pigment at50/
l, nonhomozygous for hemoglobin S, hemoglobin level at 80 g/liter,
platelets at 50/nl, leukocytes at 12/nl, lactate at 3 mmol/liter, and
blood glucose at 50 mg/dl. The asymptomatic control samples were
collected from the same region where malaria is endemic and had no
clinical signs of malaria irrespective of a few circulating parasites during
sample collection. The clinical details of the patients included in the pres-
ent study are given in Table 1.
Ethics statement. The institutional ethical committees for the Centre
for Cellular and Molecular Biology, Hyderabad, India, the Ispat General
Hospital, Rourkela, Orissa, India, and the Pt. Jawaharlal NehruMemorial
Medical College, Raipur, Chhattisgarh, India, all approved the study. In-
formed written consent was obtained from each individual.
Gene sequencing. Genomic DNA was isolated from whole blood ac-
cording to a previously described protocol (44). The reference genomic
sequences were obtained from the Ensembl database under Ensembl ID
ENSG00000165471 (www.ensembl.org). PCR and sequencing primers
were designed using NCBI Primer-BLAST (http://www.ncbi.nlm.nih.gov
/tools/primer-blast),MacVector (MacVector, Inc., USA), andAmplify 3X
software (http://engels.genetics.wisc.edu/amplify). We resequenced 8.7
kb of the MBL2 gene, which includes 	1 kb each of the upstream and
downstream regions. The target regions of MBL2 were PCR amplified
using the primer pairs MBL2_F (5=-ATTACCCTGACCCAGGCCACTG
TCTTCT-3=) and MBL2_R (5=-TACATAACATTGACCCCAAACCATA
GCAAG-3=). PCR amplifications were performed on a GeneAmp 9700
(Applied Biosystems) and using a thermal cycler (Eppendorf) with a long-
range PCR kit (Qiagen, Germany) according to the manufacturer’s pro-
tocol. The thermal cycling parameters consisted of an initial denaturation
at 93°C for 3 min, followed by 35 cycles of 45 s at 93°C, 25 s at 66°C, and 9
min at 68°C.
Only the upstream promoter and first exonic regions (	1.4 kb) were
resequenced for population samples. We PCR amplified the target region
using two primer pairs—MBL2_UPE1_1F (5=-TCTGTGACTTTCCTCC
ATTATCTGT-3=)/MBL2_UPE1_1R (5=-TGGAAGACTATAAACATGC
TTTCGG-3=) and MBL2_UPE1_2F (5=-CATTCTCATTCCCTAAGCTA
ACAGG-3=)/MBL2_UPE1_2R (5=-CTGGCAAGACAACTATTAGTCAC
AA-3=)—and an Emerald PCRmastermix (TaKaRa). The thermal cycling
parameters consisted of an initial denaturation at 95°C for 5min, followed
by 35 cycles of 30 s at 95°C, 25 s at 62°C, and 3 min at 72°C. PCR ampli-
fication was followed by Exo-SAP treatment (USBCorp., USA) according
to the manufacturer’s protocol. Exo-SAP-treated amplicons were se-
quenced directly by using a BigDye Terminator v3.1 cycle sequencing kit
(Applied Biosystems) on an ABI 3730xl DNA analyzer. The 8.7-kb frag-
ments were sequenced using 17 internal primers (see File S1 in the sup-
plemental material). Sequence variations were identified by assembling
DNA sequences with the reference sequence using AutoAssembler soft-
ware (Applied Biosystems). Variations obtained were validated and re-
confirmed in a subset of samples by resequencing and visual confirmation
of electropherograms. Novel haplotypes were reconfirmed by subsequent
resequencing.
TABLE 1 Clinical characterization of patient samplesa
Clinical parameterb
Severe malaria
(n 176)
Mild malaria
(n 101)
Parasitemia (% of infected RBCs) 2.53 1.16 1.08 0.69
Hemoglobin (g/dl) 5.68 1.37 8.93 2.40
Blood glucose (mg/dl) 43.92 13.81 80.74 19.36
Blantyre coma score 3
No. of patients
CM 71
ARF 93
IVH 83
CMARF 44
CMIVH 51
ARFIVH 56
CMARFIVH 35
Death 6
a All patients with severe malaria were hospitalized due to complications related to one
or more of the conditions listed in Table 1. Artesunate (2.4 mg/kg of body weight) was
the main antimalarial treatment given intravenously, along with other supportive
treatments, such as antibiotics, fluids, and ventilator support. Hemodialysis was
performed, when required, in cases of renal failure. All mild malaria cases recovered
with treatment uneventfully. All samples were checked for the HbS phenotype.
b CM, cerebral malaria; ARF, acute renal failure; IVH, intravascular hemolysis.
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Statistical analysis. Risk estimates of severe and mild malaria were
derived by comparison to the asymptomatic control group.We compared
genotype, allele, and haplotype distributions for (i) asymptomatic versus
mild-malaria groups, (ii) asymptomatic versus severe-malaria groups,
and (iii) mild-malaria versus severe-malaria groups. The data were ana-
lyzed using Intercooled Stata v9.1, and the level of significance was set to a
P value of 0.05. The allele and genotype frequencies were analyzed by
simple allele/genotype counting and an expectation-maximum algo-
rithm. The significance of deviations from Hardy-Weinberg (HW) equi-
librium was tested using plink v1.7 (45). The allele and genotype distri-
butions and tests of association were performed using plink. A two-tailed
Fisher exact test was performed to determine the differences in allele fre-
quencies and genotype distributions. Linkage disequilibrium (LD) analy-
sis was performed by Haploview v4.2 (46). Bonferroni corrections were
applied for multiple comparisons.
RESULTS
Sequencing of the completeMBL2 gene, along with	1 kb each of
the upstream and downstream, led to the detection of a total of 30
polymorphic loci: 29 SNPs and a 6-bp deletion in the promoter
region. We observed a novel SNP in the 3= untranslated region at
the genomic coordinate position g.54526021CA. The genotype
and allele distribution of all the variations among the case-control
groups is summarized in File S2 in the supplemental material. All
observed and investigated loci were in HW equilibrium. The de-
tected variants after exon1 do not significantly contribute in any
comparisons. The LD between the promoter and exon1 MBL2
variants in different groups is shown in Fig. 1. The promoter re-
gion of the asymptomatic group was in stronger LD compared to
the cases of mild and severe malaria. The genotype and allele dis-
tributions observed in different groups and their respective asso-
ciations are summarized in Table 2.
Odds of malaria (asymptomatic versus mild malaria). The
genotype frequencies of the promoter polymorphism221GC
(rs7096206; MBL2:Y/X) differ significantly between the asymp-
tomatic and mild-malaria groups (Table 2). The frequency of
heterozygous genotype YX (221GC) was significantly higher in
subjects with mild malaria (P 0.0021) compared to asymptom-
atic controls (after multiple correction) (Table 2 and Fig. 2). Sim-
ilarly, the frequency of allele X was significantly higher in patients
with mild malaria compared to asymptomatic controls (asymptom-
atic versus mild, P 0.0036; Table 2 and Fig. 2). These finding sug-
gests that the221GC heterozygous bears an increased risk toward
mildmalaria. None of the other variations were associated withmild
malaria (Table 2 and see File S2 in the supplemental material).
Earlier studies demonstrated that the MBL2 serum levels are
modulated by 221 G/C variant and three structural variants
of exon1. Therefore, we studied the genotypes of variants in pro-
moter (221G/C) and exon1 (codons 52 [MBL2*D], 54
[MBL2*B], and 57 [MBL2*C]) together and investigated for their
influence in serum MBL levels (high [YA/YA], intermediate [YA/
YO, XA/XA, and XA/YA], and low [YO/YO, XA/YO, and XA/XO]
MBL producers). We observed that the diplotype YA/YO was sig-
nificantly low in frequency in the group with mild malaria (P 
0.033) compared to asymptomatic individuals (Table 3 and Fig. 2).
The reconstructedMBL2 secretor haplotype distributions and
their comparison among case-control groups are summarized in
Table 4. Apart from the eight well-known MBL2 secretor haplo-
types, we observed four novel MBL2 secretor haplotypes:
MBL2*HYQA, MBL2*HYQC, MBL2*LXPB, and MBL2*LYQB.
We observed that the low-serum MBL2 haplotype MBL2*LXPA
was significantly more frequent in the group with mild malaria
compared to the asymptomatic group (P  0.0045) (Table 4).
None of the other reconstructed haplotypes contributed signifi-
cantly to association.
Odds of severe malaria (asymptomatic versus severe ma-
laria). Although the frequency of the heterozygous genotype
221GC (Y/X) was significantly higher in subjects with mild
malaria (P  0.0021), we did not determine its contribution to
severe malaria compared to the asymptomatic control (after mul-
tiple correction) (Table 2). However, the frequency of allele
221X was significantly higher in patients with severe malaria
compared to asymptomatic controls (P 0.02) (Table 2).
The distribution of the structural variantMBL2*B (rs1800451:
codon 54,GA) differed significantly between asymptomatic and
severe malaria (Table 2). The heterozygous genotype GA
(MBL2*AB) was observed significantly at high levels (P  0.03)
compared to asymptomatic controls (Table 2). Further, the fre-
quency of minor allele A (MBL2*B) was significantly greater in
cases of severe malaria (P  0.036) (after multiple corrections)
(Table 2). These findings suggest that the structural variant
MBL2*B, which interferes with oligomerization and hence the low
FIG 1 LD pattern ofMBL2 variants in asymptomatic, mild, and severe malaria groups. Empty squares indicate a high degree of LD (D= 1). Numbers indicate
the D= value expressed as a percentile.
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level of functional MBL, is a risk factor for P. falciparum malaria
(Table 2). Further, when we grouped all three structural variants
of exon1 (MBL2*D/B/C), we observed a significantly higher fre-
quency of heterozygous genotype MBL2*AO (P  0.0021) com-
pared to the control group. We also observed similar trends in
allelic distribution. The frequency of allele MBL2*O was signifi-
cantly higher in the group with severe malaria (P 0.0018) com-
pared to the asymptomatic controls (Table 2).
TABLE 2MBL2 polymorphisms present in the promoter and first exonic region and comparison of genotypes and alleles among case-control
groups
SNP position
No. (%) of patients Genotype comparisona
Asymptomatic
(n 157)
Mild malaria
(n 101)
Severe malaria
(n 176)
Asymptomatic vs mild Asymptomatic vs severe Mild vs severe
OR (95% CI) P OR (95% CI) P OR (95% CI) P
rs11003125 (550C/G)
CC (LL) 93 (59.2) 66 (65.4) 104 (59.1) R R R
GC (HL) 51 (32.5) 29 (28.7) 59 (33.5) NS NS NS
GG (HH) 13 (8.3) 6 (5.9) 13 (7.4) NS NS NS
C (L) 237 (75.5) 161 (79.7) 267 (75.9) R R R
G (H) 77 (24.5) 41 (20.3) 85 (24.1) NS NS NS
rs7096006 (221G/C)
GG (YY) 98 (62.4) 40 (39.6) 84 (47.7) R R R
GC (YX) 49 (31.2) 51 (50.5) 73 (41.5) 2.55 (1.4–4.5) 0.0021 NS NS
CC (XX) 10 (6.4) 10 (9.9) 19 (10.8) NS NS NS
G (Y) 245 (78) 131 (64.9) 241 (68.5) R R R
C (X) 69 (22) 71 (35.1) 111 (31.5) 1.9 (1.3–2.9) 0.0036 1.6 (1.1–2.4) 0.02 NS
rs7095891 (4C/T)
CC (PP) 68 (43.3) 56 (55.4) 90 (51.1) R R R
CT (PQ) 69 (44) 35 (34.6) 77 (43.8) NS NS NS
TT (QQ) 20 (12.7) 10 (9.9) 9 (5.1) NS 0.34 (0.13–0.85) 0.043 NS
C (P) 205 (65.3) 147 (72.8) 257 (73) R R R
T (Q) 109 (34.7) 55 (27.2) 95 (27) NS NS NS
MBL2* exon1 (codon 52)
CT
CC 153 (97.5) 98 (97) 162 (92.1) R R R
CT 4 (2.6) 3 (3) 14 (8) NS NS NS
TT 0 (0) 0 (0) 0 (0) NS NS NS
C 310 (98.7) 199 (98.5) 338 (96) R R R
T 4 (1.3) 3 (1.5) 14 (4) NS NS NS
MBL2* exon1 (codon 54)
GA
GG 140 (89.2) 91 (90.1) 138 (78.4) R R R
GA 16 (10.2) 10 (9.9) 36 (20.5) NS 2.3 (1.2–4.6) 0.03 NS
AA 1 (0.6) 0 (0) 2 (1.1) NS NS NS
G 296 (94.3) 192 (95) 312 (88.6) R R R
A 18 (5.7) 10 (5) 40 (11.4) NS 2.1 (1.1–3.99) 0.036 2.5 (1.2–5.6) 0.039
MBL2* exon1 (codon 57)
GA
GG 144 (91.7) 99 (98) 159 (90.3) R R R
GA 13 (8.3) 2 (2) 16 (9.1) NS NS NS
AA 0 (0) 0 (0) 1 (0.6) NS NS NS
G 301 (95.9) 200 (99) 334 (94.9) R R R
A 13 (4.1) 2 (1) 18 (5.1) NS NS 5.4 (1.3–48) 0.045
Mbl2* exon1 codons
525457
AA 125 (79.6) 87 (86.1) 108 (61.4) R R R
AO 31 (19.7) 14 (13.9) 65 (36.9) NS 2.4 (1.4–4.1) 0.0012 3.7 (1.9–7.7) 0.00008
OO 1 (0.6) 0 (0) 3 (1.7) NS NS NS
A 281 (89.5) 188 (93.1) 281 (79.8) R R R
O 33 (10.5) 14 (6.9) 71 (20.2) NS 2.1 (1.4–3.5) 0.0018 3.4 (1.8–6.7) 0.000045
a NS, not significant; R, reference. P values were corrected for multiple comparisons by Bonferroni’s method.
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Diplotype analysis shows that the frequency of the high-MBL-
producer diplotype (YA/YA) was significantly low (P 0.00003) in
the severe-malaria group compared to asymptomatic controls (Ta-
ble 3 and Fig. 2). Similarly, the high MBL2 secretor haplotypes
MBL2*LYPA andMBL2*LYQAwere significantly less frequent in the
severe-malaria group compared to the asymptomatic group
(MBL2*LYPA [P 0.015] andMBL2*LYQA [P 0.048) (Table 4).
Further, we grouped the MBL2 haplotypes into two groups: the se-
cretor haplotypes that lead to a high level of functionalMBL (HYPA
LYQA  LYPA  HYQA) made up one group, and those that
lead to a low level (LXPA LYPB LYQC HYPD LYPD
HYQC  LXPB  LYQB) made up another. We observed a sig-
nificant difference between asymptomatic subjects and those with
severe malaria. The high-MBL-producing haplotypes were signif-
icantly less frequent (P  0.00002), while the low-serum-MBL
haplotypes were significantly more frequent (P 0.00002) in the
group with severe malaria compared to the asymptomatic con-
trols (Table 4).
Oddsofmalariaprogression (mildmalaria versus severema-
laria). The exon1 structural variants (MBL2*D, MBL2*B, and
MBL2*C) differ significantly between mild and severe malaria
cases. We observed that the frequency of the minor allele A at
codon 54 (MBL2*B) was higher in severe malaria (P  0.039)
compared to mild malaria (Table 2). Similarly, the frequency of
minor allele A at codon 57 (MBL2*C) was significantly higher in
severe-malaria cases than in cases of mild malaria (P  0.045)
(Table 2). The combined genotypes of three structural variants of
exon1 show that the allele O (MBL2*D, MBL2*B, and MBL2*C)
was significantly more frequent in individuals with severe malaria
(P 0.000045) compared to those with mild malaria (Table 2).
In line to this observation, the frequency of the high-serum-
MBL secretor haplotypeMBL2*LYPA was lower in cases of severe
malaria than in themild-malaria group (P 0.02) (Table 4). This
suggests that the exon1 structural variant that affects the oli-
gomerization increases the risk of severe malaria.
MBL2 genotype and haplotype distribution in ethnic popu-
lations of India. To characterizeMBL2 polymorphisms in differ-
ent ethnic populations of India, we extended our study to 830
individuals from 32 socially, linguistically, and geographically di-
verse endogamous populations of India. The population details
and genotype distribution of functional variants (550CG,
221GC, 4CT, MBL2*D, MBL2*B, and MBL2*C) that af-
fects serumMBL levels are summarized Table 5. The frequency of
lowMBL2 secretor haplotypes varies significantly between Indian
populations (low, 0 to 62.5%) (Fig. 3). We did not observe low-
MBL2 haplotypes in two of the investigated tribal populations
(Subba and Gond), whereas an ancestral tribal population Juang
revealed a high (62.5%) frequency. However, the distribution of
the AO and XY diplotypes showed that the high prevalence of the
low-MBL2 haplotype in Juang is mainly due to promoter variant
(X, 62.50%) and not because of structural variants (O, 17.19%)
(Fig. 3). Similarly, Subba tribes had high frequencies of A
(78.13%) andY (68.75%) alleles, and the resultingmajor genotype
YA (Fig. 3). Further, theMBL2 exon1 variantMBL2*B is the prev-
alent form of structural variant in most of the Indian populations
(Fig. 3).
DISCUSSION
Mannose-binding lectin (MBL) is a soluble innate immune
pathogen recognition protein that plays a vital role in defense
during the early phase of infection (9). Several studies have shown
that MBL2 genetic variants regulate the MBL serum levels in dif-
ferent autoimmune diseases and infectious diseases, such as
malaria, leishmaniasis, leprosy, tuberculosis, schistosomiasis,
FIG 2 Distribution ofMBL2 variants in various case-control groups. (A to C)
Distribution of high-, intermediate-, and low-serum MBL2 haplotypes (A),
XY variants (B), and exon1 structural variants A and O allele (C) [(221:
rs7096206 GC, Y/X), (rs5030737: p.Arg52Cys:MBL2*D), (rs1800450:
p.Gly54Asp:MBL2*B), and (rs1800451: p.Gly57Glu:MBL2*C)]. Exon1 struc-
tural variant alleles (D, B, and C) have been designated as the O haplotype,
whereas the normalMBL2 allele is designated as A.
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trypanosomiasis, and HIV infection (9, 14–21). The clinical sig-
nificance of MBL2 variants varies with the disease context in dif-
ferent world populations (21, 47–49).
We observed significant differences in genotype and allele fre-
quencies among asymptomatic subjects and in patients with mild
and severe malaria. The genotype and allele distribution of pro-
moter polymorphism 221XY differed significantly between the
asymptomatic and mild-malaria groups, as well as between the
asymptomatic and severe-malaria groups, whereas the exon1
structural variants (MBL2*B) were associated with severe malaria
only. Individuals homozygous for structural variants in exon1
(MBL2*B, MBL2*C, and MBL2*D) were rare. None of the other
variations were associated with either mild or severe malaria. Ear-
lier studies have documented the role of other functional MBL2
promoter polymorphism (550HL) in several diseases (21, 50);
however, we did not found any statistical significance in our study.
We observed that the 221C(X) allele was found at significantly
higher frequencies in malaria cases, which increases the risk for
clinical malaria. We also observed that the structural MBL2 vari-
ants were significantly less frequent in asymptomatic subjects but
higher in the severe-malaria group, showing that individuals with
structural MBL2 variants are at higher risk for severe malaria.
Thus, our findings suggest that MBL2 variants that decrease the
plasma level of the functional MBL protein or encode dysfunc-
tional proteins make their carriers susceptible to malaria. This
result is in accordance with previous studies, which demonstrated
that the low-serum-MBL genotype is a risk factor for malarial
infection (5, 9, 32, 51); however, a study performed in Gambia
TABLE 3 Distribution of combined genotypes for variants at221G/C and exon1 at codons 52 (MBL2*D), 54 (MBL2*B), and 57 (MBL2*C)
Promoter (-221)
exon1
No. (%) of patients
Genotype comparisona
Asymptomatic vs
mild Asymptomatic vs severe Mild vs severe
Asymptomatic
(n 157)
Mild malaria
(n 101)
Severe malaria
(n 176) OR (95% CI) P OR (95% CI) P OR (95% CI) P
YA/YA 71 (45.22) 34 (33.66) 40 (22.73) NS 0.35 (0.21–0.58) 0.00003 NS
YA/YO 26 (16.56) 6 (5.94) 43 (24.43) 0.3 (0.1–0.8) 0.033 NS 5.1 (2.04–15.2) 0.0003
YO/YO 1 (0.64) 0 1 (0.57) NA NS NA
XA/YA 44 (28.02) 43 (42.57) 50 (28.41) NS NS 0.53 (0.31–0.92) 0.05
XA/XA 10 (6.37) 10 (9.90) 18 (10.23) NS NS NS
XA/YO 5 (3.18) 8 (7.92) 21 (11.93) NS 4.1 (1.4–14.3) 0.01 NS
XA/XO 0 0 1 (0.57) NA NA NA
XO/YO 0 0 2 (1.13) NA NA NA
a NS, not significant; NA, not applicable. P values were corrected for multiple comparisons by Bonferroni’s method.
TABLE 4 Distribution and comparison ofMBL2 secretor haplotypes in case and control groups
Haplotype or
comparisona
No. (%) of patients Genotype comparisonb
Asymptomatic
(n 314)
Mild malaria
(n 202)
Severe malaria
(n 352)
Asymptomatic vs mild Asymptomatic vs severe Mild vs severe
OR (95% CI) P OR (95% CI) P OR (95% CI) P
High MBL secretor
haplotypes
MBL2*HYPA 66 (21.02) 34 (16.83) 70 (19.88) NS NS NS
MBL2*LYPA 48 (15.28) 31 (15.34) 29 (8.23) NS 0.5 (0.3–0.8) 0.015 0.5 (0.27–0.85) 0.02
MBL2*LYQA 94 (29.93) 51 (25.24) 76 (21.59) NS 0.6 (0.45–0.9) 0.048 NS
MBL2*HYQA† 2 (0.66) 3 (1.48) 0 NS NA NA
Low MBL secretor
haplotypes
MBL2*LXPA 68 (21.65) 70 (34.65) 106 (30.11) 1.9 (0.3–2.9) 0.0045 1.56 (1.1–2.2) 0.042 NS
MBL2*LYPB 18 (5.73) 9 (4.45) 32 (9.09) NS NS NS
MBL2*LYQC† 8 (2.55) 0 12 (3.41) NA NS NA
MBL2*HYPD 4 (1.27) 2 (0.99) 8 (2.27) NS NS NS
MBL2*HYQC 6 (1.91) 2 (0.99) 5 (1.42) NS NS NS
MBL2*LYPD 0 0 6 (1.70) NA NA NA
MBL2*LXPB† 0 0 4 (1.13) NA NA NA
MBL2*LYQB† 0 0 4 (1.13) NA NA NA
High vs low
High‡ 210 (66.88) 119 (58.91) 175 (49.71) 0.075 0.5 (0.45–0.68) 0.00002 NS
Low§ 104 (33.12) 83 (41.09) 177 (50.28) 0.075 2 (1.5–2.8) 0.00002 NS
a †, Novel secretor haplotypes observed in this study; ‡, high expression ofMBL2* (HYPA LYQA LYPA HYQA); §, low expression ofMBL2* (LXPA LYPB LYQC
HYPD LYPD HYQC LXPB LYQB).
b NS, not significant; NA, not applicable. P values were corrected for multiple comparisons by Bonferroni’s method.
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(47) failed to replicate this association. The serum level of func-
tional MBL is mainly regulated by the promoter polymorphism
221XY and exon1 structural variantA/O (O:MBL2*D,MBL2*B,
andMBL2*C).We found all three structural variants in our study.
The genotypeYA/YAwas found to be significantly less common in
the severe-malaria group than in asymptomatic controls, whereas
genotype XA/YO was more common. We also observed that the
genotype YA/YO was significantly less common in mild-malaria
cases compared to asymptomatic subjects. These findings indicate
that a low-serum-MBL diplotype might be a risk factor for severe
malaria while the intermediate-serum-MBL diplotype might be a
risk factor for mild malaria.
Several studies have shown the effects ofMBL2 secretor haplo-
types in disease association studies (9, 21, 32).Our investigation of
the MBL2 secretor haplotype also showed significant differences
in haplotype carriages between various case-control groups. Strat-
ification of our cohort based onMBL2 haplotypes showed that the
haplotypes MBL2*LYPA and MBL2*LYQA were significantly
less common in the severe-malaria group, whereas haplotype
MBL2*LXPA was significantly less common in the mild-malaria
group. This again elucidates that the individuals with the high-
serum-MBL haplotype have low risk for malaria. In addition to
the eight common haplotypes reported previously (9), we ob-
served here four novel MBL2 secretor haplotypes, MBL2*HYQA,
MBL2*HYQC,MBL2*LXPB, andMBL2*LYQB, although atmuch
lower frequencies that were independently reconfirmed by subse-
quent sequencing procedures. The exceptional uncharacterized
secretor haplotypes MBL2*LYQB and MBL2*HXPA have also
been reported in Bakola Pygmy and Moroccan Berber popula-
tions, respectively (52).
Apart from structural variants, we did not observe any other
variations that were statistically significant between the severe-
and mild-malaria groups. The comparison shows that the struc-
tural variants are over-represented in severe cases, while the
normal variants are over-represented in the mild-malaria group,
suggesting that the severity of P. falciparum malaria is inversely
proportional to the serum level of functional MBL.
In the present study, among 32 Indian populations across In-
dia, we observed that the frequency of MBL2 haplotypes, which
leads to low level of serum MBL, varies drastically from 0% in
Subba and Gond to 62.5% in an ancestral tribal population in
Juang. The prevalence of low-MBL haplotypes in Juang is mainly
due to the prevalence of X and is not due to structural variants.
Further, high- and low-serum-MBL haplotypes are not restricted
to a particular geographic region. In the same geographic region,
populations show varied prevalences of MBL2 haplotypes and,
hence, may show different levels of susceptibility to malaria and
other infectious diseases. These findings are in agreement with the
genetic structure of Indian populations, who maintain their
unique genetic architecture, mainly due to endogamy marriage
practice over the last several thousand years. This has been well
supported by our earlier studies with mtDNA, Y chromosome,
and autosomal genetic markers (38, 39, 42, 44). We also observed
all three structural variants in exon1 (MBL2*D, MBL2*B, and
TABLE 5 Geographical origin, ethnicity, linguistic affiliation, and genotype distributions of populations in the present study
Serial
no. Population
Social
designation Language family State
Indian
regiona
Sample
size
Genotype distributionb
550CG 221GC 4CT MBL2*D MBL2*B MBL2*C
CC/CG/GG GG/CG/CC CC/CT/TT CC/CT/TT GG/AG/AA GG/AG/AA
1 Thapa Caste Tibeto-Burman Nepal Nepal 32 12:18:02 16:16:00 15:14:03 31:01:00 24:08:00 30:02:00
2 Bharia Tribe Dravidian Madhya Pradesh CI 31 18:12:01 6:20:05 20:11:00 31:00:00 22:09:00 30:01:00
3 Kol Tribe Indo-European Madhya Pradesh CI 29 15:12:02 7:12:10 22:07:00 27:02:00 24:05:00 29:00:00
4 Kurmi Caste Indo-European Madhya Pradesh CI 26 10:15:01 16:09:01 15:08:03 25:01:00 19:07:00 24:02:00
5 Kanyakubja Caste Indo-European Madhya Pradesh CI 28 19:08:01 13:14:01 14:06:08 28:00:00 24:04:00 28:00:00
6 Juang ATPc Austro-Asiatic Orissa CI 32 23:09:00 2:20:10 12:18:02 31:01:00 23:09:00 29:03:00
7 Maria Tribe Austro-Asiatic Orissa CI 80 41:36:03 42:31:07 32:38:10 76:04:00 61:18:01 71:09:00
8 Bho Tribe Indo-European Uttaranchal NI 24 15:07:02 13:10:01 7:15:02 24:00:00 20:04:00 20:04:00
9 Oraon Tribe Indo-European Jharkhand CI 28 12:13:03 15:10:03 14:11:03 27:01:00 21:06:01 26:02:00
10 Munda Tribe Austro-Asiatic Jharkhand CI 30 15:13:02 12:15:03 15:13:02 30:00:00 24:06:00 28:02:00
11 Santhal Tribe Austro-Asiatic Jharkhand CI 41 23:15:03 17:17:07 20:14:07 41:00:00 33:08:00 37:04:00
12 Rajgond Tribe Indo-European Madhya Pradesh CI 26 5:14:07 17:09:00 13:12:01 20:06:00 19:07:00 22:04:00
13 Sonker Caste Indo-European Madhya Pradesh CI 27 11:14:02 18:07:02 9:14:04 25:02:00 19:08:00 26:01:00
14 Thoti Caste Dravidian Andhra Pradesh AP 27 12:13:02 17:07:03 15:09:03 27:00:00 21:05:01 24:03:00
15 Banjara Nomadic Indo-European Rajasthan WI 35 18:13:04 24:09:02 17:17:01 34:01:00 25:10:00 34:01:00
16 Bhil Tribe Indo-European Gujarat WI 21 12:07:02 12:06:03 11:10:00 21:00:00 16:04:01 21:00:00
17 Changapa Tribe Tibeto-Burman North East NE 20 7:06:07 11:05:04 10:10:00 16:04:00 16:04:00 20:00:00
18 ChakhesNaga Tribe Tibeto-Burman Nagaland NE 18 11:06:01 14:03:01 12:06:00 18:00:00 12:06:00 18:00:00
19 Mizo ATP Tibeto-Burman Mizoram NE 20 7:12:01 13:06:01 9:10:01 20:00:00 13:07:00 19:01:00
20 Aonaga ATP Tibeto-Burman Nagaland NE 19 3:12:04 12:06:01 17:02:00 19:00:00 15:04:00 19:00:00
21 Nagaseema Tribe Tibeto-Burman Nagaland NE 24 7:12:05 12:10:02 10:11:03 24:00:00 18:06:00 23:01:00
22 Nyshi Tribe Tibeto-Burman Arunachal Pradesh NE 17 0:10:07 12:03:02 11:04:02 15:02:00 13:04:00 15:02:00
23 Bhootia Tribe Tibeto-Burman Sikkim NE 20 2:06:12 16:04:00 15:05:00 16:04:00 15:05:00 20:00:00
24 Khasi Tribe Tibeto-Burman Meghalaya NE 22 3:13:06 15:07:00 13:08:01 21:01:00 15:07:00 22:00:00
25 Puma Tribe Tibeto-Burman Sikkim NE 15 7:04:04 10:05:00 15:00:00 15:00:00 6:07:02 15:00:00
26 Sherpa Tribe Tibeto-Burman Sikkim NE 21 6:12:03 16:05:00 8:12:01 21:00:00 16:05:00 14:06:01
27 Subba Tribe Tibeto-Burman Darjeeling/WB NE 16 0:12:04 10:06:00 12:04:00 15:01:00 14:02:00 12:04:00
28 Birhor ATP Austro-Asiatic Jharkhand CI 31 13:10:08 21:07:03 16:10:05 31:00:00 25:05:01 18:10:03
29 Lambadi Tribe Dravidian Andhra Pradesh AP 19 8:09:02 13:04:02 11:06:02 9:00:00 11:07:01 11:06:02
30 Kabutariyan Caste Indo-European Uttar Pradesh NI 28 15:10:03 15:11:02 15:12:01 28:00:00 24:04:00 26:02:00
31 Gond Tribe Dravidian Chhattisgarh CI 10 3:04:03 6:03:01 5:04:01 10:00:00 10:00:00 10:00:00
32 G.Andamanese ATP Andamanese Andaman Andaman 13 1:02:10 6:05:02 13:00:00 11:02:00 13:00:00 13:00:00
Total 830
a AP, Andhra Pradesh; CI, central India; NI, north India; NE, northeast India; WI, west India; WB, west Bengal.
b Genotype distributions were in HW equilibrium at 0.05 level.
c ATP, ancestral primitive tribe.
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MBL2*C) in Indian populations. In addition, the MBL2*D/B/C
(20%) andMBL2*Y (75%) variants were observed at higher fre-
quencies in Lambadi, Rajgond, Birhor, Subba, Sherpa, Bhootia, and
Puma populations, suggesting a possible selective heterozygous ad-
vantage. MBL2*B is the most prevalent structural variant in Indian
populations, in contrast toMBL2*C in African populations.
We investigated whether MBL2 functional variants can mod-
ulate or alter serum MBL levels; hence, individuals harboring
these variants, secretor, or low or high producers have either in-
creased or decreased risk per se. In conclusion, functional MBL2
genetic variants are significantly associated with malaria patho-
genesis in Indian populations. To the best of our knowledge, this
the first study of its kind, in which we studied theMBL2 variations
in detail in diverse Indian populations. An individual with mild
FIG 3 Distribution ofMBL2 variants in 32 Indian populations across India. (A toD)Distribution ofMBL2 haplotypes (A),AO variants (B),XY variants (C), and
exon1 structural variants MBL2*B, MBL2*C and MBL2*D (D) [(221:rs7096206 GC, Y/X), (rs5030737: p.Arg52Cys:MBL2*D), (rs1800450: p.Gly54Asp:
MBL2*B) and (rs1800451: p.Gly57Glu:MBL2*C)]. Structural variant alleles (D, B, and C) have been designated asO haplotype, whereas the normalMBL2 allele
is designated as A.
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malaria can progress into amore severe form and so this is true for
severe to mild malaria or asymptomatic to mild malaria. There-
fore, further studies on ethnically different populations, as well as
larger case-control and cohort studies, are strongly recommended
in order to obtain better estimates ofmalarial risks associated with
theMBL2 polymorphism.
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